ESC Congress 2017

26 - 30 August 2017, Barcelona - Spain

Session Details

Lipid lowering therapy in primary cardiovascular prevention
Mon 28 Aug 11:00 - 12:30 Prevention - Lipids Rapid Fire Abstract Picasso - The Hub
Chairpersons: Ulrich LAUFS (Homburg, Germany)

Access slides, videos, reports online via ESC Congress 365 Other resources

List of Presentations

Related documents
11:003097Risk of incident atherosclerotic cardiovascular disease events by atherogenic lipid levels in a real-world population of 62,428 on-statin individuals with diabetes Jamal RANA (Oakland, United States of America)
11:093098Assessing gaps in cholesterol treatment guidelines for primary prevention of cardiovascular disease using clinical trial evidence: results from the prospective population-based Rotterdam StudyMaarten J G LEENING (Rotterdam, Netherlands)
11:273100Effects of morning versus evening statin therapy on lipid profile: A systematic review and meta-analysisPeter PENSON (Liverpool, United Kingdom)
11:363101Familial hypercholesterolemia: development of a next generation sequencing approach to the diseaseRossella MARCUCCI (Florence, Italy)
11:453102Comprehensive genotyping and phenotyping in patients with severe hypercholesterolemiaHayato TADA (Kanazawa, Japan)
11:543103Elevated circulating PCSK9 concentrations predict subclinical atherosclerotic and metabolic changes in low risk obese and non-obese patientsToth STEFAN (Kosice, Slovak Republic)
12:033104Associations between cardiovascular disease, cancer and very low hdl cholesterol in the reasons for geographical and racial differences in stroke (REGARDS) study.Maciej BANACH (Lodz, Poland)
12:123105Evolocumab treatment in paediatric patients with homozygous familial hypercholesterolaemia: the Trial Assessing long-term Use of PCSK9 inhibition in Subjects with Genetic LDL disorders (TAUSSIG)Frederick RAAL (Johannesburg, South Africa)
12:213106Patients with a diagnosis of hyperlipidaemia have a reduced risk of developing breast cancer and lower mortality rates: a large retrospective longitudinal cohort study from the UK ACALM registryPaul Richard CARTER (London, United Kingdom)